4.7 Article

Germline BRCA1 mutations increase prostate cancer risk

Journal

BRITISH JOURNAL OF CANCER
Volume 106, Issue 10, Pages 1697-1701

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2012.146

Keywords

prostate cancer; BRCA1 gene; mutation screening; cancer risk

Categories

Funding

  1. Prostate Action
  2. Cancer Research UK [C5047/A7357, C1287/A10118, C1287/A5260, C5047/A3354, C5047/A10692, C16913/A6135, C16913/A6835]
  3. Institute of Cancer Research
  4. Everyman Campaign
  5. Prostate Research Campaign UK
  6. Orchid Cancer Appeal
  7. National Cancer Research Network, UK
  8. National Cancer Research Institute, UK
  9. NHS
  10. Royal Marsden NHS Foundation Trust
  11. Cancer Research UK [15007] Funding Source: researchfish
  12. National Institute for Health Research [NF-SI-0510-10096] Funding Source: researchfish
  13. Prostate Cancer UK [G2011/36] Funding Source: researchfish

Ask authors/readers for more resources

BACKGROUND: Prostate cancer (PrCa) is one of the most common cancers affecting men but its aetiology is poorly understood. Family history of PrCa, particularly at a young age, is a strong risk factor. There have been previous reports of increased PrCa risk in male BRCA1 mutation carriers in female breast cancer families, but there is a controversy as to whether this risk is substantiated. We sought to evaluate the role of germline BRCA1 mutations in PrCa predisposition by performing a candidate gene study in a large UK population sample set. METHODS: We screened 913 cases aged 36-86 years for germline BRCA1 mutation, with the study enriched for cases with an early age of onset. We analysed the entire coding region of the BRCA1 gene using Sanger sequencing. Multiplex ligation-dependent probe amplification was also used to assess the frequency of large rearrangements in 460 cases. RESULTS: We identified 4 deleterious mutations and 45 unclassified variants (UV). The frequency of deleterious BRCA1 mutation in this study is 0.45%; three of the mutation carriers were affected at age <= 65 years and one developed PrCa at 69 years. Using previously estimated population carrier frequencies, deleterious BRCA1 mutations confer a relative risk of PrCa of similar to 3.75-fold, (95% confidence interval 1.02-9.6) translating to a 8.6% cumulative risk by age 65. CONCLUSION This study shows evidence for an increased risk of PrCa in men who harbour germline mutations in BRCA1. This could have a significant impact on possible screening strategies and targeted treatments. British Journal of Cancer (2012) 106, 1697-1701. doi:10.1038/bjc.2012.146 www.bjcancer.com Published online 19 April 2012 (C) & 2012 Cancer Research UK

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available